SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    J.M. Murphy, J.J. Babon, N.A. Nicola, S.E. Nicholson, Encyclopedia of Cell Biology, 2016,

    CrossRef

  2. 2
    Shuo-Chieh Wu, Loretta S. Li, Nadja Kopp, Joan Montero, Bjoern Chapuy, Akinori Yoda, Amanda L. Christie, Huiyun Liu, Alexandra Christodoulou, Diederik van Bodegom, Jordy van der Zwet, Jacob V. Layer, Trevor Tivey, Andrew A. Lane, Jeremy A. Ryan, Samuel Y. Ng, Daniel J. DeAngelo, Richard M. Stone, David Steensma, Martha Wadleigh, Marian Harris, Emeline Mandon, Nicolas Ebel, Rita Andraos, Vincent Romanet, Arno Dölemeyer, Dario Sterker, Michael Zender, Scott J. Rodig, Masato Murakami, Francesco Hofmann, Frank Kuo, Michael J. Eck, Lewis B. Silverman, Stephen E. Sallan, Anthony Letai, Fabienne Baffert, Eric Vangrevelinghe, Thomas Radimerski, Christoph Gaul, David M. Weinstock, Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia, Cancer Cell, 2015, 28, 1, 29

    CrossRef

  3. 3
    Tugba Kevser Uzuncakmak, Sarenur Yilmaz, Ayse Serap Karadag, Necmettin Akdeniz, Ibrahim Akalin, Lentiginoses in polycythemia vera patient: Is there a role forJAK2 (V617F)mutation?, JAK-STAT, 2015, 4, 1, e1071000

    CrossRef

  4. 4
    Radek C. Skoda, Adrian Duek, Jean Grisouard, Pathogenesis of myeloproliferative neoplasms, Experimental Hematology, 2015, 43, 8, 599

    CrossRef

  5. 5
    Oliver Hantschel, Unexpected Off-Targets and Paradoxical Pathway Activation by Kinase Inhibitors, ACS Chemical Biology, 2015, 10, 1, 234

    CrossRef

  6. 6
    E. Chen, A. Mullally, How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms?, Hematology, 2014, 2014, 1, 268

    CrossRef

  7. 7
    Jeffrey J. Babon, Isabelle S. Lucet, James M. Murphy, Nicos A. Nicola, Leila N. Varghese, The molecular regulation of Janus kinase (JAK) activation, Biochemical Journal, 2014, 462, 1, 1

    CrossRef